OKYO Pharma Bullish Thesis
OKYO Pharma's presentation highlights their key drug candidate, OK-101, developed to treat Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP).
Okyo Pharma Ltd (OKYO)
Market is closed
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.50 | 16,670 | Director | 16,670 | 2023-09-15 | Filing | |
| $0.08 | 5,800,000 | Officer, Director | 548,981,215 | 2022-05-19 | Filing | |
| $4.00 | 12,500 | Officer, Director | 12,500 | 2022-05-19 | Filing | |
| $4.00 | 37,500 | Large Shareholder, Officer, Director | 62,500 | 2022-05-19 | Filing | |
| $3.87 | 25,000 | Large Shareholder, Officer, Director | 25,000 | 2022-05-17 | Filing |
News See All
Billionaire Hedge Funds
